Dublin, June 30, 2025 (GLOBE NEWSWIRE) — The “Vectorized Antibodies Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges” has been added to ResearchAndMarkets.com’s offering.
The Global Vectorized Antibodies Market, valued at USD 9.49 billion in 2025, is poised for robust growth, anticipated to expand at a significant CAGR of 7.7% to reach USD 15.94 billion by 2034.
This market is at the cutting edge of biotherapeutics, employing gene therapy techniques to deliver antibody coding sequences directly into the body via viral or non-viral vectors. This novel approach reduces the need for frequent dosing of protein-based drugs, fostering prolonged in vivo production of therapeutic antibodies with the potential for prolonged efficacy and streamlined manufacturing processes.
This innovation holds substantial promise for chronic conditions such as HIV, cancer, autoimmune disorders, and rare genetic diseases, where continuous antibody presence is crucial. By merging genetic engineering precision with antibody targeting specificity, vectorized antibodies aim to enhance therapeutic outcomes and patient adherence.
As clinical trials continue demonstrating safety and efficacy, the vectorized antibodies market may redefine the landscape of biologic therapies. Manufacturing scalability and batch consistency are critical hurdles, but advances in vector production infrastructure support continued progress. The regulatory landscape is evolving, particularly in classifying gene therapies and combination products.
The report provides comprehensive insights into the vectorized antibodies market, covering market size and growth projections, trends, challenges, competitive landscape, and regional analyses across North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. It’s an invaluable resource for top management, investors, and stakeholders to strategize and capitalize on emerging opportunities.
Customization options are available, with up to 10% free customization (up to 10 analyst hours) offered to modify segments, geographies, and analyzed companies. Post-sale support includes four analyst hours, available for up to four weeks, delivered in the latest PDF and Excel formats.
Key Market Insights:
Vectorized antibodies reduce the need for repeated dosing, potentially lowering long-term treatment costs and healthcare burdens.
North America’s leadership is due to its advanced gene therapy infrastructure and supportive funding landscape, while Europe progresses with regulatory and collaborative support.
The focus is on enhancing vector payload capacity and specificity while minimizing immunogenic responses.
Applications range across oncology, infectious, autoimmune, and rare genetic diseases.
Key challenges include vector delivery efficacy, long-term safety considerations, and regulatory complexities.
North America: Leads the market, driven by investments in gene therapy research and a dynamic biotech ecosystem. Strategic collaborations between academia and industry further bolster growth.
Europe: Experiences steady growth, supported by regulatory frameworks that encourage advanced therapy medicinal products. Key players focus on optimizing vector delivery, reducing immunogenicity, and scaling production under GMP conditions.
While the market is in its early stages, it is advancing rapidly with numerous partnerships, licensing agreements, and venture capital inflows driving clinical pipeline development.
Key Attributes:
Report Attribute
Details
No. of Pages
150
Forecast Period
2025 – 2034
Estimated Market Value (USD) in 2025
$9.49 Billion
Forecasted Market Value (USD) by 2034
$18.5 Billion
Compound Annual Growth Rate
7.7%
Regions Covered
Global
Companies Featured
Adagio Therapeutics
ReiThera Srl
Voyager Therapeutics
Spark Therapeutics
Freeline Therapeutics
BioNTech SE
Moderna, Inc.
AskBio (subsidiary of Bayer AG)
Genethon
Vector BioPharma AG
Sangamo Therapeutics
Passage Bio
Gilead Sciences, Inc.
Vir Biotechnology, Inc.
Regeneron Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/osx0kq
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
People say Battle reminds them of some really good years for Britain as a country. We were entering a new millennium, everyone was running their own business, making money and the underground record industry was thriving. I wanted to do a UK garage version of Southern Freeez, by the 80s UK funk band Freeez. Initially, Battle was going to be another instrumental, and then Lain, the singer, came in the room and goes: “Let me put something on this.” I was like: “I’m not sure it’s really a vocal song.” But Lain stacked the vocals, and someone compared it to Queen’s Bohemian Rhapsody, with all the harmonies.
At the time, some people believed that I had copied a dubplate by [UK garage figure] DJ EZ. It is similar – his bassline does something like that. But I know I didn’t copy him, because I didn’t go out that much! So I’d never really heard EZ at that stage.
I didn’t know Battle was going to be as big as it was or have the impact it did – it was just another tune. Then it started to float around: a few DJs had it, the A&R people. Ears started to prick up. I think we added a level of sophistication to garage, even though people like MJ Cole and TJ Cases were already doing that. When we were trying to get Battle on the radio, one station said it was too intelligent for their listeners and they wouldn’t play it.
Battle eventually reached No 10 in August 2000. Louise Redknapp got the No 9 spot by 2,000 copies. It allowed me to appear on a TV show that I had watched my whole life as I was growing up: Top of the Pops.
A lot of people say: “Oh, garage is on the comeback.” But for me, it has been for the last 13 years. I started DJing in 2012 and every year I’m working. It’s been well received by a wider audience ever since, younger and younger.
Lain, singer
Jason Chue, AKA Wookie, was knocking about in jungle, drum’n’bass, trying to siphon off that whole energy and then putting songs to it.I remember him saying about Battle: “I’ve done something strange with the intro.” I was like: “No, just play it.” He was almost apologising for it – but it was like a godsend. That intro had such an urgency. It felt like it was piercing your soul. I said: “Give me a minute.” Then I walked out and I don’t even know if it was half an hour, but I came back and I had written all of the vocal. That’s divine. For the song title we wanted one word. There are a lot of three-word titles, but one word is strong. Whether it’s bringing up three kids on your own, or addiction, everyone’s battling through something, every day.
People call Battle a gospel song. Back then I was doing a lot of regular R&B but I really wanted to do something that involved my faith. When Jazzie B [founder of Soul II Soul and mentor to Wookie] called me about working with Jason, I thought he was going to say: “No, we don’t want that.” But he said: “Just go for it.” We had all these record label bosses trying to sign Battle – one guy had a Maserati and he blew out his speakers playing it. Months later he said: “I didn’t realise I was blowing out my speakers to a gospel tune.”
I first realised Battle was going to be big at [seminal UK garage night] Twice As Nice. Jason said: “You should come down to Twice As Nice because I think this tune’s going.” I was a bit worried because I don’t really go out. So they played the tune and everyone started going: “Booooo!” OK, that’s not a good sign. But Jason was like, “No, no, no – that means they really like it!”
Battle has endured because of what it means to the person who hears it. Back then, we would do PAs and people would say: “That song – my mum was going through cancer and that helped me.” And, 25 years later, someone said: “While I was in prison, that song got me through.” That’s everyone. That’s anyone. I remember Jason sending me a picture of someone who tattooed the middle eight of Battle on her forearm: “I can always rely / On my faith to get by.”
A new study from scientists at the Buck Institute for Research on Aging has revealed a surprising player in the battle against Alzheimer’s disease and other forms of dementia: brain sugar metabolism. Published in Nature Metabolism, the research uncovers how breaking down glycogen — a stored form of glucose — in neurons may protect the brain from toxic protein buildup and degeneration.
Glycogen is typically thought of as a reserve energy source stored in the liver and muscles. While small amounts also exist in the brain, particularly in support cells called astrocytes, its role in neurons has long been dismissed as negligible. “This new study challenges that view, and it does so with striking implications,” says Professor Pankaj Kapahi, PhD, senior scientist on the study. “Stored glycogen doesn’t just sit there in the brain; it is involved in pathology.”
The research team, led by postdoc Sudipta Bar, PhD, discovered that in both fly and human models of tauopathy (a group of neurodegenerative diseases including Alzheimer’s), neurons accumulate excessive glycogen. More importantly, this buildup appears to contribute to disease progression. Bar says tau, the infamous protein that clumps into tangles in Alzheimer’s patients, appears to physically bind to glycogen, trapping it and preventing its breakdown.
When glycogen can’t be broken down, the neurons lose an essential mechanism for managing oxidative stress, a key feature in aging and neurodegeneration. By restoring the activity of an enzyme called glycogen phosphorylase (GlyP) — which kicks off the process of glycogen breakdown — the researchers found they could reduce tau-related damage in fruit flies and human stem cell-derived neurons.
Rather than using glycogen as a fuel for energy production, these enzyme-supported neurons rerouted the sugar molecules into the pentose phosphate pathway (PPP) — a critical route for generating NADPH (nicotinamide adenine dinucleotide phosphate) and Glutathione, molecules that protect against oxidative stress. “By increasing GlyP activity, the brain cells could better detoxify harmful reactive oxygen species, thereby reducing damage and even extending the lifespan of tauopathy model flies,” said Bar.
Even more promising, the team demonstrated that dietary restriction (DR) — a well-known intervention to extend lifespan — naturally enhanced GlyP activity and improved tau-related outcomes in flies. They further mimicked these effects pharmacologically using a molecule called 8-Br-cAMP, showing that the benefits of DR might be reproduced through drug-based activation of this sugar-clearing system. “This work could explain why GLP-1 drugs, now widely used for weight loss, show promise against dementia, potentially by mimicking dietary restriction,” said Kapahi.
Researchers also confirmed similar glycogen accumulation and protective effects of GlyP in human neurons derived from patients with frontotemporal dementia (FTD), strengthening the potential for translational therapies. Kapahi says the study emphasizes the power of the fly as a model system in uncovering how metabolic dysregulation impacts neurodegeneration. “Work in this simple animal allowed us to move into human neurons in a much more targeted way,” he said.
Kapahi also acknowledges the Buck’s highly collaborative atmosphere as a major factor in the work. His lab, with expertise in fly aging and neurodegeneration, took advantage of proteomics expertise in the Schilling lab and the Seyfried lab (at Emory University) as well as the Ellerby lab which has expertise in human iPSCs and neurodegeneration.
Kapahi says this study not only highlights glycogen metabolism as an unexpected hero in the brain but also opens up a new direction in the search for treatments against Alzheimer’s and related diseases. “By discovering how neurons manage sugar, we may have unearthed a novel therapeutic strategy: one that targets the cell’s inner chemistry to fight age-related decline,” he says. “As we continue to age as a society, findings like these offer hope that better understanding — and perhaps rebalancing — our brain’s hidden sugar code could unlock powerful tools for combating dementia.”
Coauthors: Additional Buck collaborators include Kenneth A. Wilson, Tyler A.U. Hilsabeck, Sydney Alderfer, Jordan B Burton, Samah Shah, Anja Holtz, Enrique M. Carrera, Jennifer N. Beck, Jackson H Chen, Grant Kauwe, Tara E. Tracy, Birgit Schilling, and Lisa M. Ellerby. Other collaborators include Eric B. Dammer, Fatemeh Seifar and Nicholas T. Seyfried, Emory Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA as well as Ananth Shantaraman, Department of Biochemistry, Emory University School of Medicine, Atlanta, GA
Acknowledgments: The work was supported by NIH grants R01AG038688, R21AG054121, AG045835, R01AG071995, R01AG070193, T32AG000266-23, R01AG061879, P01AG066591 and 1S10 OD016281. Other support came from the Hevolution Foundation, American Federation of Aging Research, the Larry L. Hillblom Foundation and the CatalystX award from Alex and Bob Griswold
The drag artist known as The Vivienne died from misadventure after suffering cardio-respiratory arrest after taking ketamine, a coroner has ruled.
James Lee Williams, 32, was found in the bath by a neighbour at their home in Chorlton-by-Backford, Cheshire, on Sunday 5 January. The last time anyone had contact with them was two days earlier, a court was told, when a friend said it was evident the entertainer had taken ketamine.
Five drug snap bags were found in The Vivienne’s property, including in a bedroom drawer and a bin in the bathroom, an inquest at Warrington coroner’s court heard on Monday.
Although the performer had struggled with drugs in the past, Williams’s family told the hearing they should not be remembered for their use of ketamine and that drugs did not define the person they were.
Friends and family had no worries about Williams’s mental health, the hearing was told, and the performer was looking forward to future roles on TV and in the theatre, although did “occasionally” take ketamine.
Jacqueline Devonish, the senior coroner for Cheshire, concluding the inquest, said: “The medical cause of death is cardio-respiratory arrest due to ketamine use. The conclusion, on the balance of probabilities, is that I’m satisfied that James Williams’s death was a misadventure, he took ketamine but he did not intend to take his own life.”
A report from a toxicologist, Dr Kerry Taylor, said tests showed a relatively high level of ketamine, but not at a level normally causing death. However, the drug can cause drowsiness, seizures and heart stimulation, and the concentration may have dissipated over time.
Williams was the winner of the first series of RuPaul’s Drag Race UK and years later spoke about having been a drug addict. In April, their sister, Chanel Williams, questioned whether the “stigma” surrounding drug use had prevented them from seeking help.
She told the BBC Two current affairs programme Newsnight that The Vivienne did not discuss their relapse, including a hospital stay, to “protect” their family, after a “really long period of sobriety”.
“It’s hard for me because I think, if that stigma wasn’t there, would my brother have sought the help he needed?” she said. “To think that, if we’d known, or if he’d have felt able to talk and really reach out for the help that was needed, the outcome could’ve been different. That’s why we’ve shared James’s story.”
Williams’s family have said they would work with the drug charity Adferiad on future campaigns. Their sister has called for ketamine to become a class A drug rather than class B, because people “think it’s less harmful than other drugs”.
The government is seeking expert advice as the illegal use of ketamine has surged to record levels.
The media accreditation system for the New Delhi 2025 World Para Athletics Championships is now open.
International Media is invited to apply for accreditation clicking here. The accreditation period for Indian-based media and photographers will be open at a later stage.
The deadline to apply for international media accreditation is 25 July 2025.
Available categories for media accreditation are as per below:
• Press • Photographer • Rights-holding Broadcasters • Non-rights-holding TV and Radio Broadcaster
Professionals will be contacted about their accreditation status after this date. Completion of the registration process does not automatically guarantee accreditation.
Please note that nationals from certain countries may require a short-term stay visa to enter India. For more information and to confirm if you come from a country or region that requires a visa to enter India visit https://india-evisa.it.com.
If you have any questions, please contact media@WorldParaAthletics.org.
New data from a prespecified subgroup analysis of the phase 2 Actuate-1801 part 3B trial (NCT03678883) highlight the potential of elraglusib (9-ING-41), an investigational glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with gemcitabine/nab-paclitaxel (GnP) for first-line metastatic pancreatic adenocarcinoma (mPDAC) treatment.1
The findings indicate a notable improvement in overall survival (OS) among patients receiving at least 1 complete cycle of elraglusib in conjunction with standard chemotherapy, particularly within the challenging subgroup of patients with liver metastases.
For patients who completed at least one 4-week cycle of therapy, the elraglusib/GnP combination arm achieved a median OS of 12.5 months compared with 8.5 months in the control arm. This represented a 43% reduction in the risk of death relative to the control group, underscoring the potential for early disease control with elraglusib.
Beyond OS, the combination therapy also demonstrated improved outcomes across several other key efficacy metrics. The disease control rate (DCR) was 53.4% in the elraglusib arm vs 44.8% in the control arm, while the overall response rate (ORR) improved to 37.9% compared with 29.3%. Median progression-free survival (PFS) was 6.9 months with elraglusib, an improvement over 5.6 months in the control group.
A particularly impactful finding emerged from the analysis of patients with liver metastases; a subpopulation historically associated with an exceptionally poor prognosis in mPDAC. In this group, treatment with elraglusib led to a 2.5-fold increase in 1-year OS and a 38% reduction in the risk of death compared to the control arm. While the GnP control arm showed 0% OS probability at 18 months, patients receiving elraglusib maintained a survival probability of 13.6% OS at 18 months. Additional efficacy metrics within this liver metastases subgroup further supported these observations: DCR was 36.8% vs 27.9%, ORR was 29.8% vs 19.7%, and PFS was 4.9 months vs 3.9 months in the elraglusib and control arms, respectively. The pronounced benefit observed in this high-risk population highlights elraglusib’s potential to address a critical unmet need.
“We are highly encouraged by the significant clinical benefit provided by elraglusib demonstrated in this study,” said Daniel Schmitt, president and chief executive officer of Actuate Therapeutics, in a press release. “These results underscore the potential of elraglusib to generate rapid and durable benefit in high-risk patients, which could be highly impactful in future development and commercial pathways.”
mPDAC represents an advanced and aggressive disease and accounts for approximately 90% of all pancreatic cancers. It is widely recognized as one of the deadliest malignancies, with a 5-year survival rate for metastatic cases under 10%.2 This prognosis underscores the urgent need for novel and more effective therapeutic strategies.
Elraglusib’s mechanism of action involves the inhibition of GSK-3β, a serine/threonine protein kinase implicated in numerous cellular processes, including cell proliferation, differentiation, and survival.1 GSK-3β plays a complex role, often promoting tumor growth and contributing to resistance against conventional cancer therapies, such as chemotherapy. By inhibiting GSK-3β, elraglusib aims to disrupt key molecular pathways in cancer that are involved in promoting tumor growth and resistance. Specifically, its activity targets pathways such as NF-kB of activated B cells and the DNA damage response.
Furthermore, preliminary research suggests elraglusib may also mediate antitumor immunity through the regulation of multiple immune checkpoints and immune cell function, potentially enhancing the body’s natural defenses against cancer. These multifaceted effects contribute to the drug’s observed clinical benefits.
REFERENCES:
1. Actuate Therapeutics highlights significant and sustained survival benefit in key metastatic pancreatic cancer patient populations in phase 2 elraglusib trial. News release. Actuate Therapeutics. June 24, 2025. Accessed June 26, 2025. https://tinyurl.com/muyufn2j
2. Sarantis P, Koustas E, Papadimitropoulou A, et al. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173-181. doi:10.4251/wjgo.v12.i2.173
The Boeing 747 continues to be recognized as one of the most iconic commercial jets of all time. Originally introduced in the 1960s, the game-changing aircraft brought unprecedented capacity, range, and comfort to the commercial aviation industry. After its launch, airlines across the world flocked to the type, with some even continuing to operate it today. The 747 and most of its variants are undoubtedly a major success.
Launch Customer(s)
Pan American World Airways
First Delivery
January 22, 1970
Last Delivery
January 31, 2023
Number Delivered
1,573
While the 747 was a commercial success, it has served important roles in aviation beyond passenger operations. The aircraft was famously operated by the United States’ National Aeronautics and Space Administration (NASA), where two modified 747 variants carried the Space Shuttle, the aircraft used for recurring space travel. NASA’s impressive feat of using the jet comes with several interesting facts and a colorful history, further solidifying that the Boeing 747 was the true Queen of the Skies.
The Shuttle Carrier Brought The Space Shuttle Back To Florida
Photo: Carla Thomas NASA | Wikimedia Commons
The Boeing 747s used to carry NASA’s Space Shuttle were known as “Shuttle Carrier” aircraft. The aircraft were used between 1977 and 2012, according to the National Air and Space Museum. The aircraft’s primary purpose was to transport the Space Shuttle from its landing location back to the Kennedy Space Center near Cape Canaveral, Florida. This purpose made the Shuttle Carrier a critical link in NASA’s space flight ambitions.
Both aircraft involved in the program were modified Boeing 747 jets. The aircraft had to undergo several changes to safely transport such a massive piece of equipment, but still, the jets hold significant resemblance to the base model of the Boeing 747. Both aircraft were Boeing 747-100 variants, according to NASA. The first aircraft in the program was acquired from American Airlines in the mid-1970s, not long after the first Boeing 747 entered commercial service.
Since the program’s launch, the Shuttle Carrier has become an iconic symbol of the United States’ space exploration aspirations. Though the Space Shuttle, and thus its carriers, are no longer in service, many remember the striking and rather unusual appearance of a 747 lifting off with another aircraft attached to the top of its fuselage. But for that to be possible, the aircraft underwent some major enhancements and modifications to be capable of transporting the Space Shuttle.
Major Modifications Were Made To The Shuttle Carriers
Photo: Udo Haafke | Wikimedia Commons
Because they were carrying such a large aircraft on top of their fuselages, both Shuttle Carrier jets were given some major enhancements. Three struts and their respective structural strengthening in the aircraft’s interior were placed on top of the Shuttle Carriers. In addition to improving the strength of the fuselage, it provided a place for the orbiter to be attached to the aircraft.
The engineers also added enhanced horizontal stabilizers for improved directional stability. These were attached to the aircraft’s existing horizontal stabilizers, giving a unique and recognizable look to the aircraft’s tail section. Less visible to the public was the removal of the aircraft’s entire interior and cabin, which was necessary given that the aircraft was coming from a commercial airline.
More advanced instruments to be used by flight crews were also installed. The primary purpose of these added systems were to monitor electrical loads of the orbiter during ferry flights. All of these changes, while certainly costly, made the 747 capable of carrying the Space Shuttle. Beyond these modifications, the aircraft’s appearance remained remarkably close to a standard Boeing 747.
Related
How The Boeing 747 Made A Comeback At Delta Air Lines
30 years after the carrier initially retired the jumbojet, it made a comeback to its fleet.
The First Shuttle Carrier Did More Than Ferry Aircraft
Photo: NASA | Wikimedia
While the Shuttle Carrier was immortalized for its role in US space exploration, before it was converted into a ferry aircraft, the first jet in the program was actually used for a different purpose upon its arrival at NASA. According to NASA, the government agency used it to perform a series of flight tests at the Armstrong Research Center in Edweards, California. These tests shaped Federal Aviation Administration regulations that were designed to ensure safety for aircraft operating in wake turbulence.
The tests focused on the phenomenon of wake turbulence, which is often found in the path of large aircraft. Though typically causing minor bumps, in the right conditions, it could pose a threat to the safety of flights that are following larger aircraft. These tests provided the foundation for new flight procedures for arriving and departing commercial aircraft. While used for NASA, it seems the Shuttle Carrier has also contributed to ensuring daily commercial aircraft operations remain safe.
Following the aircraft’s time with flight tests focused on wake turbulence, it was sent to Boeing to be modified to carry the Space Shuttle. Though the aircraft had important contributions to the world of aviation, its most popular role would not start until changes were made by its manufacturer. The first Shuttle Carrier was utilized until November 1990, before its replacement aircraft was deployed.
NASA’s Second Shuttle Carrier Also Logged An Impressive History
Photo: NASA
The second Boeing 747-100 to enter the Shuttle Carrier program was first built in 1973. The jet initially entered service with Japan Airlines, but was ultimately obtained by NASA in 1989. Like with the original 747 Shuttle Carrier, the second aircraft was modified by Boeing. Upon the completion of the necessary modifications, the aircraft was delivered to NASA on November 20, 1990. It would remain with the agency for over two decades.
The aircraft was officially retired in February 2012, marking the end of an iconic and impressive chapter for NASA and the United States’ space exploration efforts. By the time the aircraft was removed from service, it had completed an impressive amount of work for NASA. Among its achievements were:
Flight Hours
33,004
Flights With Shuttle
66
The Shuttle Carrier program proved to be a successful one for NASA, and has demonstrated the impressive capabilities of the Boeing 747 and other modern, commercial jets. Despite the Boeing 747’s success, the aircraft is becoming an increasingly rare sight in the skies across the world. It won’t be much longer before airlines follow NASA’s move and retire the aircraft type entirely.
Related
Which Boeing 747 Variant Was Used As The Shuttle Carrier Aircraft?
Both aircraft were ex-commercial passenger jets.
The 747 Is An Increasingly Rare Jet
Photo: Vincenzo Pace | Simple Flying
Unfortunately for 747 fans, the aircraft is reaching the end of its service life. Though it might take longer for freighter airlines (which have embraced the jet) to completely retire the 747, in the commercial segment of the aviation industry, the aircraft has quickly lost favor. The 747’s four engines make it far less efficient than modern twin-engine jets, leading airlines to retire their fleets of the Queen of the Skies in favor of smaller, more cost-efficient aircraft.
Though the 747’s reign is coming to an end, it boasts a long and successful career in connecting the world. Some of the 747’s largest passenger operators over its lifespan include Japan Airlines, British Airways, Singapore Airlines, and United Airlines. Additionally, major cargo carriers like Atlas Air and Kalitta Air invested heavily in the type.
The 747 has become an iconic aircraft that revolutionized flying. Though it may soon disappear from the skies, it will likely be remembered for years to come. Countless 747s are displayed in museums across the world, keeping the memory of the famous jet alive. Additionally, for fans of the 747, Lego recently released a new set featuring the 747’s role as a Shuttle Carrier.
747 Fans Can Now Purchase A Lego Shuttle Carrier Model
Photo: Lego
Fans of NASA, Lego, or the 747 might enjoy one of Lego’s newest products: a replica of the Shuttle Carrier. The set comes with the pieces to assemble both the 747-100 and Space Shuttle, unlocking a new way to preserve and appreciate the aircraft’s legacy. This set costs about $230 and comes with a whopping 2,417 pieces.
This isn’t the first tribute to modern aviation Lego has made. The company already sells a Concorde model, immortalizing the only supersonic passenger jet. Lego fans have embraced the kit, potentially paving the way for more aviation-themed Lego sets. The price of the Shuttle Carrier set also indicates Lego’s confidence in demand and excitement for the product.
This Lego set, among countless other memorials to the Shuttle Carrier and the Boeing 747, demonstrates the widebody aircraft’s role in shaping modern travel and even space exploration. As the jet continues to be retired by commercial carriers, many are still celebrating the aircraft’s contributions to modern travel. Whether it’s displays in museums, Lego kits, or other experiences, the legacy of the Boeing 747 and the Shuttle Carrier is being kept alive by fans and stakeholders across the world.
